Complete Neutralization of Live COVID-19 Virus Via Revolutionary Patented Vaccine Technology
PULLMAN, WA and SALT LAKE CITY, UT Dec. 4, 2020 – Hexamer Therapeutics Inc. (“HTI”) and Innovative Vaccine Technologies (“IVT”) announce they are collaborating to develop and manufacture a safe, highly scalable and effective novel type of COVID-19 vaccine. This joint effort utilizes HTI’s revolutionary patented vaccine technology consisting of a novel self-assembling vaccine (strings of natural amino acids) combined with an adjuvant proven safe for the elderly, the vaccine sensitive, and the immune compromised. IVT will manage and optimize vaccine manufacturing and distribution in partnership with global leaders in peptide manufacturing.
“Our most recent preclinical studies show complete biological and physical neutralization of live SARS-CoV-2 virus in vitro, and we have very encouraging results with high antibody titers, a durable T-Cell response and strong binding to targets on the virus S-Protein.” — Dr. Colin Collins, Chief Scientific Officer and Co-Founder HTI.
“The leap from traditional vaccine production to our highly scalable manufacturing technology is a breakthrough similar to the transition from vacuum tubes to silicon microprocessor chips.” — Robert Bogden, CEO and Co-Founder of HTI.
Numerous advantages are generated through the technology and joint collaboration:
- Manufacturing Safety: The self-assembling vaccine is made from simple peptides and does not rely on chickens, bacteria or mammalian cells for production.
- Fast: In just days, vaccines can be produced for mutant viral strains or bioterrorist outbreaks.
- Scalable: Millions of human grade vaccines can be delivered in only weeks and billions in a few months.
- Stable: Vaccines are stockpiled and stored for many years at room temperature.
- Patriotic: All vaccine components are 100% American made.
- Versatile: The platform can be armed with a variety of antigenic targets (SARS-CoV-2, Influenza, N1H1, H5N1, Ebola, Anthrax, etc.).
- Inexpensive: Each dose is delivered at a fraction of the cost of other vaccines.
- Durable: A single dose of vaccine provides long term protection durability.
- Safe: Proven to be more effective and predicted to be safer than mRNA based vaccines.
For more information contact:
Robert Bogden
CEO and Co-Founder
Hexamer Therapeutics Inc.
Email: bogden@hexthera.com
Web: hexamertherapeutics.com
Dr. Colin Collins
CSO and Co-Founder
Hexamer Therapeutics Inc.
Email: ccollins@hexthera.com